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5General Introduction
Obesity
Obesity is a result of uncontrolled expansion of the adipose tissue and is associated with
severe health risks (1). The most widely used index of obesity is the body mass index
(BMI), which is calculated by dividing body weight in kilograms by the square of height in
meters (kg/m2). BMI between 18.5 and 25 is considered to be normal weight, BMI ranging
between 25.0 and 29.9 is defined as overweight, and a score of 30 or above indicates
obesity. Obesity has reached epidemic proportions in western industrialized countries. In
the USA approximately 30% of all adults are estimated to be obese, up to 60% are
considered overweight, and the prevalence in children is increasing dramatically (2, 3). It is
also a rising problem in Norway where a recent report states that 14.7% of men and 12.5%
of women are obese (4).
Obesity is directly linked to a number of different health risks. The most common obesity-
related health condition is hypertension. The prevalence of type 2 diabetes has been shown
to increase with increased body weight in both men and women and although coronary
heart disease can not be directly linked to overweight it shows a significantly higher
prevalence in obese individuals (5). There is also evidence that obesity increases the risk of
certain types of cancer such as colon cancer and breast cancer (6).
Obesity is a consequence of a positive energy balance in the body, where consumed energy
exceeds energy expenditure. This is due to both environmental and hereditary factors (7).
Availability and composition of food as well as reduced requirement for physical activity
are some environmental factors that have changed in recent years and contribute to a
positive energy balance. Some of the genes involved have been characterized but a lot
remains to fully understand how these components work in a physiological environment.
Energy balance is composed of energy intake and energy expenditure. Energy intake is
regulated by feeding and will be discussed below.
Energy expenditure can be divided into three categories: basal metabolism, physical
activity, and adaptive thermogenesis (8). The first is the obligatory energy expended on
basic cellular and physiological functions. The maintenance of energy balance requires
6oxidization of the fuel that is ingested. Obese individuals who have lost weight are less
effective in increasing fat oxidation in the presence of a high-fat diet than normal weight
individuals (6). The energy expended in physical activity is directly related to body weight
and it has been shown that exercise can accelerate the adaptation to a change from a low-
to a higher-fat diet (9). Adaptive thermogenesis refers to the thermic effect of food and the
ability to convert excess calories to heat. After food is ingested there is a rise in energy
expenditure. This process is partly controlled by the sympathetic nervous system.
Thermogenic activity of brown adipose tissue (BAT) is also under sympathetic nervous
system control. This activity is primarily mediated in brown adipocytes by mitochondrial
uncoupling protein 1 (UCP1) which allows protons to leak across the inner mitochondrial
membrane instead of coupling these protons to ATP synthesis (10). This results in
increased heat production. BAT is abundant in small animals and human infants but in
adult humans the amount of BAT is minimal. It is therefore thought that the expression of
UCP1 is not substantial to be physiologically meaningful in adults. A homologue of UCP1,
UCP3 is expressed predominantly in skeletal muscles. A strong association between the
expression of UCP3 and fat metabolism has been established but the nature of this
association remains unknown (11).
Signaling of energy balance
Food intake in humans is influenced by emotional factors, social factors, and learned
behavior (12). In addition to this, systems within the brain sense and integrate signals
regarding energy stores and recent energy intake to maintain energy homeostasis. The
hypothalamus integrates both peripheral and central signals and controls food intake, levels
of physical activity, energy expenditure, and endocrine systems. Some of these signals are
regarded as short-term and include signaling molecules from the gut in response to meals
(13). More long-term signals include factors that are secreted from adipose tissue such as
leptin, adiponectin, resistin, and visfatin, and insulin secreted from the pancreas (Fig. 1).
7Figure 1. Integration of long-term and short-term signals of energy balance in the brain. Adipose tissue
and the pancreas produce peripheral signals that relate to long-term energy stores. Short-term signals
include absorbed nutrients and peptides secreted from the gut. Figure from Badman and Flier 2005 (12).
The gut is known as a source of signals that influence appetite. Stretch sensors in the
gastro-intestinal tract send signals directly to the brain via afferent nerves and in addition
there are a number of different endocrine signals secreted that can affect appetite.
Cholecystokinin (CCK) is a prototypical satiety hormone that is produced in mucosal
endocrine cells in the small intestine. It is secreted by these cells in response to the
presence of food within the gut lumen. Sulfated CCK binds to CCK receptors on vagal
afferent neurons, which transmit neural signals to the brainstem and results in a reduction
in meal size (14). CCK receptors also inhibit gastric emptying, which may enhance the
signals of satiety. Infusion of CCK into human subjects has been shown to suppress food
intake and cause earlier meal termination (15). Glucagon-like peptide 1 (GLP-1) is another
satiety peptide and is secreted from L-cells in response to nutrients in the form of free fatty
acids and carbohydrates. GLP-1 inhibits gastric acid secretion and emptying and stimulates
insulin release (16). Another peptide that stimulates insulin secretion is glucose-dependent
insulinotropic polypeptide (GIP). GIP secretion from the small intestine is primarily
induced by absorption of ingested fat. It has been shown that mice lacking the GIP receptor
that were fed a high-fat diet were protected from obesity (17). Peptide YY (PYY) and
pancreatic polypeptide (PP) belong to the same peptide family and are both 36 amino acid
8long, tyrosine containing peptides (18). PYY is produced in endocrine cells in the ileum
and colon and is secreted after meals to delay gastric emptying. It binds to Y2 receptors in
the hypothalamus which inhibit neuropeptide Y (NPY) positive neurons and depresses
feeding (19).  Intravenous infusion of physiological levels of PYY reduces caloric intake
(20, 21). PP is released from pancreatic islet cells and act on Y4 and Y5 receptors. It
reduces both appetite and food intake without affecting gastric emptying (22). On the other
hand, a peptide that stimulates hunger is ghrelin. This is a hormone secreted from cells
located throughout the gastro-intestinal tract. It is known for appetite stimulating actions
though activation of NPY expressing neurons (23). Intravenous injection of ghrelin to
normal weight human subjects increases food intake (24). This might be useful in the
treatment of anorexia.
The role of insulin in the adaptive response to peripheral changes in the energy balance is
well known. Secretion of insulin by pancreatic β-cells after a meal leads to glucose transfer
into cells followed by energy production. A receptor-mediated transport system of insulin
across the blood brain barrier (BBB) was described in the 1980s (25) and led to the
proposal that insulin also might play a role in more long-term regulation of the energy
balance. It has been shown that administration of insulin within the central nervous system
suppresses food intake in rodents and sub-human primates and regulates expression of
hypothalamic neuropeptides that influence appetite (26). In addition, deletion of insulin
receptors in neurons produces obesity in mice (27).
White adipose tissue (WAT) is a loose connective tissue that is dispersed throughout the
body and positioned subcutaneously and surrounding every internal organ. WAT was long
regarded only as a storage compartment for excess energy with triglycerols constituting
more than 85% of the tissue weight (28). It is now known that the adipocytes secrete many
different cytokines known as adipokines, and the adipose tissue is therefore regarded as an
endocrine organ. The endocrine function of WAT may be best characterized by the
secreted factor leptin. The ob gene, which codes for the 16-kDa protein leptin, was first
cloned in 1994 by Zhang et al (29), the year after the leptin receptor was characterized
(30). A frequently used model of obesity is the ob/ob mice which have a homozygous
mutation in the ob gene (31). These mice are leptin deficient, which results in hyperphagia,
morbid obesity, diabetes, and other health complications. Complete leptin deficiency is not
9a frequent cause of human obesity, only very few individuals have homozygous loss-of-
function mutants of leptin or its receptor (32), but a syndrome of partial leptin deficiency
might be more common (33).
Leptin circulates as both a free and bound hormone. The levels of both adipose tissue and
plasma leptin are dependent on the amount of energy stored as fat as well as the status of
the energy balance. Leptin levels are elevated in obese individuals (34) and increase with
high-energy intake, while lean individuals have lower leptin levels. Leptin receptors are
mainly located in appetite-modulating neurons in the hypothalamus (35). Leptin enters the
brain by a saturable transport mechanism, possibly by receptor-mediated transcytosis
across the BBB (36). The long form of the leptin receptor activates Janus kinase-signal
transducer and activator of transcription (JAK-STAT) signaling among other signal
transduction pathways (37). The product of the ob gene was named leptin, from Greek
leptos meaning thin, because it decreased bodyweight and fat mass when injected into mice
(38).  It is now understood that leptin also serves as an important signal of starvation when
levels are low. This function is likely to be as important as its antiobesity role. The fact that
leptin levels are elevated in most obese individuals is thought to indicate a state of leptin
resistance. Two general mechanisms of leptin resistance have been proposed. The first may
involve a defect in receptor-mediated leptin transport across the BBB to sites within the
brain critical to regulation of energy balance (39). The other mechanism involves members
of the suppressors of cytokine signaling (SOCS) family. SOCS3 is induced in
hypothalamic neurons in a leptin dependent manner and is an antagonist of leptin signaling
(40).
The adipose tissue secrets many other endocrine factors in addition to leptin (some of
which are shown in Fig. 1). Adiponectin is an adipocyte-secreted collagen like protein that
circulates at high concentrations (41). Levels of adiponectin are reduced in obesity, and the
suppression correlates with insulin resistance (42). Levels can be induced by treatment
with antidiabetic thiazoladinediones (TZDs). Resistin is another secreted protein and is
induced in obesity. It might be in part responsible for systemic insulin resistance (43). The
adipose tissue is known for its ability to metabolize sex steroids. The most important role
of the sex steroids is in fat distribution. Estrogens stimulate adipogenesis in the breast and
in subcutaneous tissue, while androgens promote central obesity (44). Central obesity has
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been associated with insulin resistance, type 2 diabetes, hypertension, and coronary heart
disease (44). Inflammatory cytokines such as tumor necrosis factor α (TNF-α) and
interleukin 6 (IL-6) are also produced and secreted by the adipose tissue. TNF-α regulates
key components of fat metabolism, and has a net effect to prevent obesity through
inhibition of lipogenesis, increased lipolysis, and facilitation of adipocyte death via
apoptosis (45). IL-6 is an immune modulating cytokine which expression in adipocytes is
increased in obesity. IL-6 deficient mice develop late-onset obesity that can be prevented
by low-dose infusion of IL-6 into the brain (46, 47). The identity of upstream pathways
responsible for this “inflammatory state” within adipose tissue remains an unanswered
question.
As mentioned earlier, the hypothalamus is the main center for integrating signals that
influence energy balance. Many signaling pathways involved in feeding and energy
expenditure in the brain are activated and the best characterized of these is the
melanocortin pathway (Fig. 2). This pathway involves two populations of neurons within
the arcuate nucleus. One population expresses the orexigens (feeding-inducing) NPY and
agouti related protein (AgRP), while the other population coexpresses mRNAs encoding
the anorexigenic peptides cocaine and amphetamine related transcript (CART) and
proopiomelanocortin (POMC) which is cleaved to α-melanocortin stimulating hormone
(α-MSH) (26). AgRP and α-MSH are antagonistic ligands of the G protein-coupled
receptor melanocortin 4 receptor (MC4R) (48). The activation of MC4R by α-MSH
reduces food intake, while suppression of MC4R by the antagonist AgRP increases feeding
(49). The dominant mutation causing the obese phenotype of the Ay mouse, another rodent
obesity model, is due to ubiquitous expression of the coat color protein agouti (50). Agouti
causes obesity by antagonizing the action of α-MSH on MC4Rs within the brain (51).
There are different models on how these melanocortin signals produce downstream effects
on appetite, energy expenditure, and neuroendocrine function. One of these models
involves direct projection of the arcute melanocortinergic neurons (AgRP and POMC) onto
neurons located within the lateral hypothalamus that express the orexigenic peptides
melanin-concentrating hormone (MCH) and orexin (52). MCH stimulates food intake (53).
Some of the functions of leptin can be understood through the actions of the melanocortin
pathway. Leptin signaling induces the expression of CART and α-MSH, while the action
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of leptin reduces the expression of NPY and AgRP (52), explaining the reduction of food
intake when leptin levels rise.
Figure 2. The melanocortin pathway. Simplified representation of potential action of gut peptides and
adipose factors on the hypothalamus. Circulating agents enter into the arcuate nucleus of the hypothalamus
through the blood brain barrier. Integration of peripheral signals within the brain involves an interplay
between the hypothalamus and hindbrain structures. Red - appetite-inhibiting neurons, green - appetite-
stimulating neurons, → direct stimulatory, ⊥. – direct inhibitory. Figure from Badman and Flier 2005 (12).
Adipogenesis
The adipose tissue is comprised of lipid-filled cells (adipocytes) surrounded by a matrix of
collagen fibers, blood vessels, lymph nodes, fibroblasts, nerves and immune cells. It is an
important component of the body’s system of energy balance, and the major energy reserve
in higher eukaryotes. Adipocytes are derived from mesenchymal stem cells which can also
differentiate into muscle cells and chondrocytes under the right conditions (54).
Adipogenesis, the differentiation of preadipocytes into mature adipocytes, is highly
regulated in a temporal manner and is a well-characterized process in vitro (55). The cell
systems most widely used for studying adipogenesis in vitro are the preadipocyte cell lines
3T3-F442A and 3T3-L1 that are already committed to the adipocyte lineage (56). More
recently, studies have also been performed using pluripotent mesenchymal stem cells that





Mouse models, where important adipose factors are over-expressed or knocked out, also
present new knowledge about adipocytes and adipogenesis (31, 60).
3T3-L1 preadipocytes are morphologically similar to fibroblasts. After induction of
differentiation the cells convert to a spherical shape, start to accumulate lipid droplets, and
acquire morphological and biochemical characteristics of mature white adipocytes.
Initially, preadipocytes enter growth arrest when they reach confluence, although cell-cell
contact is not strictly required for growth arrest to occur (61, 62). The initial phase of
growth arrest is followed by one or two additional rounds of mitosis, known as mitotic
clonal expansion (MCE). MCE is a prerequisite for differentiation of 3T3-L1
preadipocytes into adipocytes (63).
Growth arrest and MCE are accompanied by complex changes in gene expression. Many
different transcription factors are critical to adipocyte differentiation (Fig.3); the most
important factors will be discussed here. Expression of CCAAT/enhancer-binding protein-
β (C/EBPβ) and C/EBPδ has a temporal rise during MCE (64), and it has been established
that C/EBPβ is required for MCE to take place (65). C/EBPβ and C/EBPδ are two of the
members of the C/EBP family of transcription factors. These proteins contain a highly
conserved basic leucine zipper domain which mediate homo- and hetero-dimerization, and
are expressed in a variety of tissues (66). Recent gain- and loss-of function studies indicate
that these proteins have a profound effect on fat cell development (67). Expression of
C/EBPα in adipogenesis is thought to be transcriptionally activated by C/EBPβ (68).
C/EBPα activates the expression of many adipocyte genes, including adipocyte-specific
fatty acid binding protein (aP2), lipoprotein lipase (LPL), glycerophosphate dehydrogenase
(GAPDH), and fatty acid synthase, which give rise to the adipocyte phenotype. In addition
to activating the expression of C/EBPα, C/EBPβ also activates transcription of the
peroxisome proliferator-activated receptor-γ (PPARγ) (68). A positive feedback loop exists
that mutually reinforces the expression of C/EBPα and PPARγ. PPARγ is a member of the
nuclear receptor protein subfamily that forms heterodimers with the retinoid X receptor
(RXR). It regulates gene transcription through the binding to response elements as a
heterodimer complex with RXRs. Use of high-affinity selective PPARγ agonists TZDs and
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Figure 3- Transcription factors involved in adipogenesis. The figure summarizes some of the transcription
factors that are most critical to adipogenesis and some of the factors critical to the adipocyte phenotype.
Some factors expressed in preadipocytes must be down-regulated in order to initiate adipogenesis. Retinoic
acid (RA), retinoic acid receptor (RAR), preadipocyte factor-1 (Pref-1), leukemia inhibitory factor (LIF),
high-mobility group I (Y) (HMGI(Y)), C/EBP homologous protein-10 (CHOP10), adipocyte determination
and differentiation factor 1 (ADD-1), sterol regulatory element binding protein-1c (SREBP-1c), inhibitor of
DNA binding (Id), phosphoenolpyruvate carboxykinase (PEPCK).
Many intracellular and extracellular signals influence the growth of preadipocytes and
terminal differentiation. Only some of the most important will be included here. Insulin is
produced in pancreatic β  cells and is involved in short-term regulation of energy
homeostasis. It increases the percentage of cells that differentiate into mature adipocytes in
vitro and also increases the amount of lipid accumulated in each fat cell (69) although it is
not required for the differentiation of all preadipose cell lines (70). Preadipocytes express
few insulin receptors and the effect of insulin on differentiation has been shown to occur
through cross activation of the insulin-like growth factor receptor-1 (IGF-1) (56).
Downstream signaling of insulin and IGF-1 include stimulation of Ras. Ectopic expression
of activated Ras has been reported to induce adipogenesis without the need for hormonal
stimulation (71). Ras is an activator of the mitogen-activated protein kinase (MAPK)
pathway. The role of the MAPK pathway in adipogenesis will be discussed below. Akt is
another downstream effector of insulin action. Expression of a constitutively activated
allele of Akt in 3T3-L1 cells induces their spontaneous differentiation (72).
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Glucocorticoids have been used for many years to optimize differentiation of cultured
preadipose cell lines. The synthetic glucocorticoid dexamethasone is the most widely used
glucocorticoid. It is thought to operate through the activation of the glucocorticoid
receptor, which is a member of the nuclear receptor superfamily. Dexamethasone induces
expression of C/EBPδ, which is involved in the early stages of differentiation (73). It has
also been reported that dexamethasone reduces the expression of preadipocyte factor-1
(Pref-1), a negative regulator of adipogenesis (74). cAMP is also known to promote
differentiation by inducing the transcription factor C/EBPβ (64). Isobutylmethylxanthine
(IBMX) is a phoshodiesterase inhibitor that increases the half-life of cAMP and thereby
potentiating agents that act by stimulating adenylyl cyclase, increasing the levels of cAMP
in the cell. In addition, a variety of cytokines and growth factors have been found to
suppress fat cell differentiation. The most studied proteins include TNF-α, IL-1, epidermal
growth factor, and platelet-derived growth factor. The mechanisms underlying the effects
of these factors are still unknown, though suppression of expression of key adipogenic
factors have been observed (75).
The MAPK signaling pathway
MAPKs are important mediators of signal transduction and play a key role in regulation of
many cellular processes, such as cell growth and proliferation, differentiation, and
apoptosis as well as more short-term changes required for homeostasis and acute hormonal
responses (76). Mammalian MAPK pathways can be activated by a wide variety of
different stimuli acting through diverse receptor families, including hormones and growth
factors that act through receptor tyrosine kinases, peptides acting through G protein-
coupled receptors (GPCRs), transforming growth factor (TGF)-β-related proteins acting
through Ser-Thr kinase receptors, and environmental stresses such as osmotic shock and
ionizing radiation (77). Three groups of MAPKs have been well characterized;
extracellular signal-regulated kinases (ERKs), c-Jun amino-terminal kinases (JNKs), and
p38 MAPKs (Fig. 4). The last two families of MAPKs are often referred to as stress-
activated protein kinases (SAPKs) which also includes the recently described ERK5 sub-
family (78). The MAPKs are serine/threonine kinases regulated by phosphorylation
cascades organized in specific modules. All modules include two additional protein kinases
that are activated in series and lead to activation of a specific MAPK. MAP kinase kinases
(MAPKKs) activate the MAPKs through phosphorylation on tyrosine and threonine
15
residues within a conserved Thr-X-Tyr motif in the kinase activation loop. Both the
tyrosine and the threonine residue must be phosphorylated for the MAPKs to be active; as
a consequence the MAPKs can be deactivated by all three major groups of protein
phosphatases, serine/threonine phosphatases, tyrosine phosphatases, or dual specificity
phosphatases (discussed below) (79). The MAPKKs are regulated by Ser/Thr
phosphorylation, catalyzed by MAPK kinase kinases (MAPKKKs). The MAPK pathways
are organized in complexes by scaffolding or linker proteins and although specific MAPK
pathways are activated through specific signaling, several MAPKs may phosphorylate the































Mitogen-Activated Protein Kinase Signaling Cascades
Figure 4. Overview of the MAPK signaling cascades. The classic MAPK cascade consists of three
sequential intracellular protein kinase activation steps and is initiated when a MAPKKK is activated and
phosphorylates a MAPKK, which subsequently activates a MAPK. The activated MAPKs translocate to the
nucleus to activate numerous proteins including transcription factors.
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The ERK pathway is preferentially activated by mitogens such as serum or growth factors
and is an important regulator of cell cycle and proliferation (80). Most cell surface
receptors can activate the Ras GTPases. Ras GTPases comprise a large family of mostly
membrane-resident proteins that shuttle between an inactive GDP-bound and an active
GTP-bound conformation (81). Activated Ras can bind to a number of different effector
molecules, including the serine/threonine kinase Raf. All three Raf family members, A-
Raf, B-Raf, and Raf-1 can bind to Ras. After binding to Ras, Raf can be activated by
members of the Rho GTPase family through phosphorylation mediated by p21-activated
kinase as well as by other kinases including Src and protein kinase C (82). Ras independent
activation of Raf has also been reported (79). Raf in turn activates the dual-specificity
kinases MAPK/ERK kinase 1 (MEK1) and MEK2 by phosphorylating two serines in the
MEK activation loop (83, 84). MEK1/MEK2 are localized to the cytoplasm where they
bind ERK1/ERK2 which are the only known substrates of MEK (85). Phosphorylation of
ERK leads to dissociation of ERK from MEK and translocation from the cytosol to the
nucleus. Within the nucleus ERK phosphorylates many transcription factors including
nuclear factor-κB, c-Myc, cyclic AMP response element binding protein, and activating
protein 1 (86).
Cytokines, different ligands for GPCRs, agents that interfere with DNA and protein
synthesis, and many types of stress including UV and γ-irradiation activate the JNK
pathways (87). There are three known mammalian isoforms of JNK; JNK1, JNK2, and
JNK3 (79). The dual-specificity kinases MKK4 and MKK7 are known to directly activate
JNK (88, 89). MKK4 and MKK7 transmit signals from many upstream activators such as
apoptosis signal-regulating kinase-1 (ASK-1), mixed lineage kinases (MLKs), and
MKKK1-4 (90). JNK inhibitory protein (JIP) is known to bind kinases at each level of the
JNK pathway and is thought to act as a scaffolding protein (87). When activated, JNK
activates different transcription factors such as c-Jun, activating transcription factor 2
(ATF-2), p53 and c-Myc (90). In addition, JNK also phosphorylates non-transcription
factors such as Bcl-2 and Bcl-xL, which is known to inhibit the anti-apoptotic activity of
these proteins (91).
Members of the p38 MAPK family were first identified as kinases that were strongly
activated by cytokines and were involved in pro-inflammatory activity (78). Four isoforms
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of p38 MAPK have been identified (α, β, γ, and δ) and in addition to being activated by
cytokines these kinases are also activated by different forms of cellular stress such as UV
irradiation and osmotic shock (76). MKK3 and MKK6 are thought to be the major kinases
responsible for p38 MAPK activation (79). Similar to the JNK pathway, MKK3 and
MKK6 are also activated by the upstream protein kinases ASK1, MKKKs, and
transforming growth factor-beta-activated kinase 1 (TAK1). In addition, Rho family
GTPases take part in the regulation of p38 MAPK activity (90). p38 MAPKs control the
function of transcription factors, kinases, and phosphatases such as ATF-2, myocyte-
specific enhancer factor 2, and cell division cycle protein 25 (cdc25) (90). p38 MAPK
pathways are involved in a variety of cellular responses including cell death (92), cell
growth (93), and differentiation (94).
The role of MAPKs in adipogenesis
The development of obesity and expansion of the adipose tissue is a result of both
hypertrophy and hyperplasia of adipocytes. Several studies have analyzed the role of
MAPKs in differentiation of established preadipocyte cell lines in vitro. Because of its
essential role in cell proliferation and the fact that adipogenic stimuli, such as insulin,
activate the ERK pathway, the role of this pathway in adipogenesis has been extensively
investigated (95-102).  Initial studies reported that ERK is required for differentiation of
3T3-L1 cells. It was shown that the expression of transfected Ras oncogenes led to
differentiation of 3T3-L1 cells into adipocytes in the absence of insulin, while transfection
of a dominant inhibitory Ras mutant resulted in inhibition of differentiation (71). Since the
oncogenic form of Ras protein is a strong activator of the ERK pathway, this suggests a
positive role for ERK in adipogenesis. Another study confirmed these results by the use of
an antisense strategy to decrease expression of ERK in 3T3-L1 cells. Knock-down of ERK
blocked DNA synthesis by ~90% and prevented the differentiation of 3T3-L1 fibroblasts
into adipocytes (101). Later, the discovery that ERK phosphorylates PPARγ and that this
reduces the transcriptional activity of this adipogenic transcription factor and inhibits
adipocyte differentiation (97, 99) made the picture more complicated. A specific MEK
inhibitor, U0126, that was administered to 3T3-L1 cells during MCE, was shown to block
differentiation (63). Other studies again found a positive role for ERK in adipocyte
differentiation. The phosphorylation of C/EBPβ by ERK enhanced the DNA-binding
activity of this transcription factor (102) and the activation of MEK/ERK signaling has
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also been linked to enhanced expression of  C/EBPα and PPARγ (100). These results
indicate the importance of ERK activity early in adipogenesis. PPARγ expression is not
detected during MCE and increases during terminal differentiation. On the other hand,
ERK activity has been shown to decrease during later stages of differentiation (98), which
could be necessary to avoid negative PPARγ phosphorylation (80). Preadipocyte cell lines
have been extensively used to investigate the role of ERK in adipogenesis, but other model
systems have also provided useful information. Activation of the ERK pathway has been
shown to be required during early stages of adipocyte differentiation in embryonic stem
cells (57). The use of ERK1-/- mice has also linked ERK to the regulation of adipocyte
differentiation in vivo. ERK1-/- mice have decreased adiposity and fewer adipocytes than
wild-type animals and are also resistant to high-fat diet induced obesity (96).
p38 MAPK is active in preadipocytes and early stages in adipogenesis. This activity
decreases dramatically during later stages of differentiation. Treatment of 3T3-L1 cells
with two different p38 MAPK inhibitors prevented the differentiation of these cells into
adipocytes (103). It was shown in the same study that C/EBPβ bears a consensus site for
p38 MAPK phosphorylation and serves as a substrate for p38 MAPK in vitro. The same
p38 MAPK inhibitors also impaired transcriptional induction of PPARγ. Later it was
shown that the induction of a constitutively active form of MKK6, an upstream activator of
p38 MAPK, was sufficient to stimulate 3T3-L1 cells to differentiate into adipocytes (98).
However, prolonged activation of p38 MAPK leads to cell death.
JNK has also been reported to be active at early stages of differentiation. Studies
addressing JNK and its role in adipogenesis and obesity include evidence that PPARγ is
phosphorylated by JNK and that this phosphorylation decreases PPARγ-dependent
transcriptional activity (104). Studies using different rodent obesity models show that the
absence of JNK1 results in decreased adiposity and that JNK activity is abnormally
elevated in obesity (60).
MAPK phosphatases (MKPs)
Protein phosphorylation is a critical posttranslational modification that is involved in the
regulation of many cellular activities. MAPK activation requires phosphorylation on a
threonine and tyrosine residue within the activation loop of the kinase domain. Both
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duration and magnitude of activation is crucial in determining the physiological outcome in
the cell (105). Dephosphorylation is vital for the control of MAPKs and is carried out by
protein phosphatases. Dephosphorylation of either the tyrosine or the threonine residue can
result in enzymatic inactivation (106). Both protein serine/threonine phosphatases and
protein tyrosine phosphatases have been reported to dephosphorylate MAPKs (107).
Another family of phosphatases that has been recognized as key players for inactivating
different MAPK isoforms is the MAP kinase phosphatases (MKPs). MKPs are dual
specificity phosphatases (DSPs) that can dephosphorylate both the tyrosine and the
threonine residue within the kinase activation domain. Activation of MAPKs can result in
immediate gene transcription of important cellular proteins and cytokines as well as the
transcription of MKPs. The transcription of MKPs provides a negative feedback
mechanism for MAPK activity (108).
All MKPs share amino acid sequence identity, in particular in two domains. The dual
specificity phosphatase catalytic domain contains the highly conserved consensus sequence
-HCXXXXXR-, where X represents any amino acid, localized within the carboxyl-
terminal half of these enzymes. The active site cleft in the DSP domain is able to
accommodate both the phosphorylated tyrosine and threonine residues within the MAPK
kinase domain (108, 109). The cysteine and arginine residues within the signature motif in
the active site, and an additional highly conserved aspartate residue are essential for
catalyzing the dephosphorylation reaction (106). In addition to the conserved motif in the
active site, the MKPs also share sequence identity in two short regions in the N-terminal
that are homologous to sequences in the cdc25 phosphatase. These motifs are catalytically
inactive and their function is at present unknown.
In 1992 MKP-1 was identified as the first member of the MKP family (110). Sequence
comparisons indicated strong similarity to the protein tyrosine phosphatase VH1 that was
identified the previous year in vaccinia virus (111). Later, several other members of the
MKP family have been characterized. To date there are 14 identified members. The MKPs
are structurally and functionally distinct and can be grouped into four categories as listed
below (108) (see Table 1 and Fig. 5).
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Table 1. Overview of the members of the MKP family. The table summarizes presently known features of the
MKP proteins and includes names of the mouse and human orthologues, structure, substrate preference, and
subcellular localization. Recently, a new addition to the MKP family was made, MKP-8 (112).  This table is








MKP-6 DUSP-14 ERK ~ JNK >> p38 - NM_019819




VHR DUSP-3 ERK >> JNK ~ p38 Nuclear NM_028207
Type II MKP-1 DUSP-1 p38 ~ JNK >> ERK Nuclear NM_013642
MKP-2 DUSP-4 ERK ~ JNK ~ p38 Nuclear AK080964
MKP-3 DUSP-6 ERK >> JNK ~ p38 Cytosolic NM_026268
MKP-4 DUSP-9 ERK ~ JNK ~ p38 Nuclear/
Cytosolic
AY_316312
MKP-X DUSP-7 - Cytosolic NM_153459
PAC-1 DUSP-2 ERK >> p38 ~ JNK Nuclear U09268
VH3 DUSP-5 - Nuclear XM_140740
Type III MKP-5 DUSP-10 p38 ~ JNK > ERK Nuclear/
Cytosolic
NM_022019
Type IV MKP-7 DUSP-16 JNK ~ p38 >> ERK Cytosolic NM_130447





Type I MKPs are approximately 200 amino acid residues in length and contain only the
DSP domain. The three members that have been identified to date are MKP-6 (113), DSP2
(114), and VHR (115).
Type II MKPs
Type II MKPs are between 300 and 400 amino acid residues in length and contain an N-
terminal MAP kinase-binding (MKB) domain in addition to the DSP domain. Members
identified so far include MKP-1 (110, 116), MKP-2 (117), MKP-3 (118), MKP-4 (119),
MKP-X (120), PAC-1 (121) and VH3 (122). These MKPs display different specificities
towards MAPK substrates (see Table 1). Little is known about the specificity of MKP-X
and VH3 towards MAPKs but both are known to dephosphorylate the ERK MAPK.
Type III MKPs
The only member identified in this subgroup so far is MKP-5. It is approximately 500
amino acid residues in length. In addition to the DSP domain and MKB domain
characteristic of the type II MKP subgroup, MKP-5 also contains an N-terminal domain of
unknown function (123, 124).
Type IV MKPs
Type IV MKPs are between 600 and 700 amino acids in length and contain both the DSP
domain and MKB domain. In addition, members of this subgroup contain a sequence of
approximately 300 residues C-terminal to the DSP domain. This sequence is rich in proline
(P), glutamine (E), serine (S), and threonine (T) residues and is therefore referred to as a
PEST sequence. It might be involved in degradation of type IV MKPs through ubiquitin-
mediated proteolysis, which could be an important regulatory mechanism (125). The
members of this subgroup include MKP-7 (126) and VH5 (127).
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Figure 5. Subgrouping of the MKP family according to structure. MKP family members and characteristics
of each group are described in the text. Figure from Farooq et al. 2004 (108).
Although much is known about the domains of the MKPs the structural basis of enzyme-
substrate interactions and the mechanism of dephosphorylation of MAPKs are still not
clear. The study of the crystal structure of an inactive mutant of VHR in complex with a
biphosphorylated substrate has given some information to the mechanism of
dephosphorylation (109),  but more studies including three-dimensional structures of
MKPs  alone and  in complex with MAPKs is necessary to complete the picture. What is
already known is that many of the MKPs become catalytically activated through protein-
protein interactions with different MAPKs. MKP-1 (128), MKP-2 (129), MKP-3 (130),
MKP-4 (130), MKP-X (131), and PAC-1 (132) have all been reported to be catalytically
activated upon substrate binding. In the cases of MKP-3 and PAC-1 it is known that this
activation is due to a conformational change (132, 133). MKP-5 (123) is not reported to be
activated upon substrate binding. VHR (109) and VH3 (134) are known to be in an optimal
confirmation for catalysis.
Aim of the study
As documented in the introduction above, obesity is an increasing health problem in
western industrialized countries. In short, obesity is a result of the expansion of the adipose
tissue, both by hyperplasia and hypertrophy of the adipose cells. Based on present
knowledge that MAPK activity is reduced during adipogenesis and that the MKPs are a
family of phosphatases known to mediate the dephosphorylation of MAPKs, the goal of
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Manuscript
Expression and regulation of Mitogen Activated Protein Kinase
(MAPK) Phosphatases (MKPs) in adipogenesis
Summary
Obesity has reached epidemic proportions in western industrialized countries and can be
linked to a number of health risks such as hypertension, type 2 diabetes, coronary heart
disease, and certain types of cancer. Obesity is due to a positive energy balance in the body
that results in expansion of the adipose tissue caused by both hyperplasia and hypertrophy
of adipocytes. Previous studies have found that MAPK activity is required in early stages
of adipogenesis. It has also been reported that two of the MKPs, phosphatases known to
dephosphorylate MAPKs, have a role in adipocyte differentiation. Based on this
knowledge we carried out a systematic analysis of the expression and possible regulation
of members of the MKP family during differentiation of 3T3-L1 preadipocytes. Results
showed that most members of the MKP family are down-regulated during adipogenesis.
We hypothesized that ectopic expression of one of the MKPs that was significantly down-
regulated at early stages of differentiation, MKP-5, would have an effect on adipogenesis.
Retroviral expression of MKP-5 in 3T3-L1 cells had a positive effect on adipocyte
differentiation. In rodent obesity models ob/ob and Ay, most of the MKPs showed up-
regulation in white adipose tissue, including MKP-5, with especially dramatic differences
in subcutaneous fat depots. Although further studies are needed to verify these data, the




Obesity has reached epidemic proportions in western industrialized countries. In the United
States nearly 30% of the adult population are considered obese and up to 60% are
considered overweight (1); in Norway the percentage of the population that is obese has
increased drastically during the past 10 years and is now approximately 13% (2).
A number of severe health risks are directly linked to obesity, such as hypertension,
coronary heart disease, type 2 diabetes, and certain types of cancer (3, 4). Obesity is a
result of a positive energy balance in the body where the consumed energy exceeds the
energy expended and is related to expansion of the adipose tissue. Energy homeostasis is
highly regulated and the main centre for integrating signals regarding the body’s energy
state is the hypothalamus (5). Both long-term and short-term signals are integrated in this
part of the brain and result in efferent outputs, such as regulation of appetite, energy
expenditure, reproduction, and growth (6). Short-term peripheral signals are mainly meal
related and are secreted by the gut while the adipose tissue secretes signals related to
energy stores in a more long-term manner. Many systems have been used to study obesity
and the role of adipose genes such as the established rodent obesity models ob/ob and Ay.
These mouse models have mutations in genes involved in the regulation of the body’s
energy balance and have obese phenotypes, as well as other known characteristics (7).
The expansion of the adipose tissue related to obesity is due to both hyperplasia and
hypertrophy of the adipose cells, which is the main component of this tissue. Given that
mature adipocytes do not undergo cell division it is thought that increase in adipocyte
number in vivo is a result of proliferation and differentiation of preadipocytes, also present
in adipose tissue. This differentiation process, often referred to as adipogenesis, is
especially well characterized in the established mouse preadipocyte cell lines 3T3-L1 and
3T3-F442A, where the expression and sequential induction of many different proteins and
transcription factors has been described (8, 9). In short, the cells first undergo a limited
number of cell divisions, known as mitotic clonal expansion (MCE) (10), then the cells
become quiescent and start expressing adipocyte-specific genes, accumulate lipid droplets,
and acquire biochemical and morphological characteristics of mature white adipocytes.
Many intracellular and extracellular signals are known to influence the growth of
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preadipocytes and induce terminal differentiation. These work through several different
intracellular signaling pathways, one of which is the MAPK pathway.
MAPK signaling is activated by many different stimuli, such as mitogens, inflammatory
cytokines, growth factors, and stress (11). Three main groups of MAPKs have been
identified; ERK, JNK, and p38 MAPK, and these are known to be key regulators of diverse
cellular processes, such as cell growth and proliferation, differentiation, and apoptosis (12).
Several studies have analyzed the role of MAPKs in adipocyte differentiation. ERK has
been shown to both induce and inhibit adipogenesis (13-16), something that at first seemed
contradictory. Later, a hypothesis emerged stating that ERK activation is required for early
stages of adipogenesis, but needs to be turned off for terminal differentiation (17). Both
p38 MAPK and JNK have also been shown to be active early in adipogenesis (18). This
activation is reduced towards the end of differentiation. In addition, JNK has been reported
to affect adiposity in rodent obesity models (19).
MAPKs are activated by phosphorylation of both threonine and tyrosine residues in their
kinase domain (20). The activation is mediated by upstream kinases and subsequently
dephosphorylation by phosphatases is important in regulating their activity. A family of
dual specificity phosphatases, also known as MAP kinase phosphatases (MKPs), has been
recognized as key players for inactivating different MAPK isoforms (21, 22). To date, 14
different MKPs have been identified. They share some common features, such as a
catalytic phosphatase domain, but they have also been reported to have distinct substrate
specificity, different tissue distribution, and different subcellular localization (23).
One MKP of special interest in this study is MKP-5. Two different groups identified MKP-
5 as a new member of the MKP family in 1999 (24, 25). MKP-5 is evenly distributed in
both the cytoplasm and the nucleus of COS-7 and NIH3T3 cells. Studies of the ability of
MKP-5 to dephosphorylate MAPKs indicate selectivity for p38 MAPK and JNK in COS-7
cells, NIH3T3 cells, and a human prostate carcinoma cell line (24-26), but it also showed
some activity towards ERK in COS-7 cells (25).
Two members of the MKP family have previously been studied for their possible role in
adipogenesis. One study found that MKP-1 was increased at both the mRNA and protein
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levels during differentiation (27). Knock down of MKP-1 reduced adipogenesis, an effect
that was attributed to sustained activation of ERK throughout adipogenesis. Another study
found that MKP-4 has an inhibitory effect on adipogenesis (28). The levels of MKP-4 are
low in 3T3-F442A preadipocytes and are up-regulated during differentiation. MKP-4 has
also been suggested to play a role in insulin resistance which is a fundamental aspect of
type 2 diabetes, one of the most common health risks related to obesity (28). These
previous results indicate a role for members of the MKP family in adipogenesis.
Since MAPKs have been implicated for adipogenesis and the MKPs are known to play a
key role in their regulation we investigated the possible regulation of known members of




TRIzol reagent, glutaraldehyde, hygromycin, and SuperScript II reverse transcriptase were
purchased from Invitrogen. Penicillin/Streptomycin, L-glutamine, Trypsin, and DMEM
were purchased from Bio-Whittaker-Cambrex. Neomycin, Oil Red O, insulin, IBMX,
dexamethasone, oligo(dT), fetal calf serum (FCS), Triton X-100, HePes, EDTA, MgCl2,
NaCl, dithiothreiol (DTT), β -g lycerophosphate ,  sod iumor tovanada te ,
phenylmethylsulphonyl-fluoride (PMSF), leupeptin, Tween 20, bovine serum albumin
(BSA), horseradish peroxidase-conjugated anti-rabbit IgG antibody, horseradish
peroxidase-conjugated anti-mouse IgG antibody, and anti-α-tubulin mouse monoclonal
antibody were from Sigma-Aldrich. LightCycler instrumentation, capillaries, and
LightCycler® FastStart DNA Master SYBR Green I were obtained from Roche. The phase
contrast microscope was from Olympus. Bradford solution, Precision Plus Protein dual
protein marker and PVDF membrane were obtained from Bio-Rad Laboratories. T4 DNA
Ligase, BamHI and HindIII restriction enzymes were from New England Biolabs. The
pGEM-T Easy vector was obtained from Promega. pREV-TRE and pRevTet-Off retroviral
vectors were delivered by BD Biosciences.  QIAquick Gel Extraction Kit was purchased
from QIAGEN. PhusionTM High-Fidelity DNA Polymerase and DyNAzymeTM II DNA
Polymerase were from Finnzymes. Anti-phospho-JNK polyclonal antibody, anti-total JNK
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antibody, anti-phospho-ERK antibody, and anti-total ERK antibody were from Cell
Signaling. MKP-5 antibodies were obtained from Abcam and Imgenex. Horseradish
peroxidase-conjugated anti-goat IgG antibody was purchased from Santa Cruz
Biotechnology. The aP2 antiserum was a generous gift from Gökhan Hotamisligil,
Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston,
USA. Adipose tissue was a generous gift from Arne Klungland, Rikshospitalet University
Hospital, Oslo, Norway. Hepa1c1c-7 cells were a generous gift from Trond Berg,
Department of Molecular Biosciences, University of Oslo, Norway. J55 cells were a
generous gift from Inger Sandlie, Department of Molecular Biosciences, University of
Oslo, Norway.
Cell culture
3T3-L1 cells and BOSC cells (viral packaging cells) obtained from ATCC were grown in
DMEM supplemented with 10% fetal calf serum (FCS), 50U/ml penicillin, 50µg/ml
streptomycin and 2mM L-Glutamine. The cells were incubated at 37°C in a humidified 5%
CO2, 95% air incubator. Differentiation of 3T3-L1 cells was induced by adding 0.5mM
isobutylmethylxanthine (IBMX), 1µM dexamethasone and 5µg/ml insulin to cells grown
to confluence. After 48 hours the cells were re-fed with DMEM supplemented with 10%
FCS and 5µg/ml insulin for 12 days. Cells were harvested at the following points: 50%
confluence (day -2), 100% confluence (day 0), 2, 4, 6, 8, or 12 days after changing the
medium and supplementation with 5µg/ml insulin. 3T3-L1 cells stably expressing MKP-5
and control cells infected with empty vector were kept in DMEM containing 20% fetal calf
serum and differentiation was induced as described above, in the absence of selecting
agent.
Oil Red O staining
3T3-L1 cells were fixed at the indicated time points using 0.5% glutaraldehyde/PBS for 10
minutes and stained with 0.15% of the triglyceride specific dye, Oil Red O, until
aggregates started to form (approximately 15 min). Cells were then rinsed in PBS and 60%
isopropanol prior to photography using a phase contrast microscope with the 20×objective.
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RT-PCR
Total RNA was extracted from 3T3-L1 cells, mouse adipose tissue, Hepa1c1c-7 cells, and
J55 cells using the TRIzol reagent, following the manufacturer’s instructions. 2-5µg RNA
was reverse transcribed using SuperScript II reverse transcriptase and oligo(dT) primers.
Gene specific primers were designed by the web-based program Primer3 Output
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). In each set the 3´and 5´
primers were chosen from different exons to avoid genomic amplification. This was later
confirmed by performing RT-PCR on cDNA samples synthesized in the presence or
absence of SuperScript II reverse transcriptase. Samples that were not reverse transcribed
did not give PCR products. Primer sequences and conditions are listed in table 1.
Each PCR reaction contained 3µl template, 0.2mM dNTP, 0.2µM of each primer, and 1U
DyNAzymeTM II DNA Polymerase in a total volume of 25µl. PCR conditions included an
initial denaturation step at 94°C for 5 minutes, followed by 35 cycles of 94°C denaturation
for 30 seconds, 60-64°C annealing for 30 seconds (see Table 1 for the annealing
temperature for different primer pairs), and 72°C extension for 90 seconds.
Quantitative PCR
The same primers as described above were used for quantitative PCR, which was carried
out on LightCycler instrumentation. Each PCR reaction contained 1µl cDNA template,
0.5µM of each primer, 2-4mM MgCl2, and 0.25µl LightCycler® FastStart DNA Master
SYBR Green I in a total volume of 10µl added to LightCycler capillaries. MgCl2
concentrations and temperature conditions were optimized for each primer pair. Cycling
conditions include an initial denaturation step at 95°C for 10 minutes, followed by 45
cycles of 95°C denaturation for 10 seconds, 60-64°C annealing for 5 seconds (see Table 1),
and 72°C extension for 20 seconds.  A negative control, containing only water as template,
was included for each primer pair. Melting curve analysis was performed for each reaction
to confirm specific PCR products. SYBR Green I, a double-stranded DNA specific dye,
was used for continuous fluorescence monitoring. The crossing point (CP) values, defined
as the cycle at which the fluorescence of the sample rises significantly above the
background fluorescence, were used to determine relative expression of the specific gene.
All relative concentrations were normalized to a housekeeping gene to compensate for
variations in quality and quantity of different samples. The ribosomal protein 36B4 mRNA
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was used as a housekeeping gene for 3T3-L1 cells (29). All data analysis was performed
using Microsoft Excel.
Cloning and vectors
MKP-5 was amplified from cDNA made from RNA of 50% confluent 3T3-L1 cells using
PhusionTM High-Fidelity DNA Polymerase and primers (MKP-5 open reading frame
(ORF)) as specified in Table 1. The PCR product was run on a 1% agarose gel, and the
fragment was isolated from the gel using QIAquick Gel Extraction Kit following the
manufacturer’s instructions. The isolated PCR product was A-tailed using DyNAzymeTM II
DNA Polymerase before ligation into the pGEM-T easy vector using T4 DNA Ligase. The
sequence of the insert was then verified by sequencing before further use. MKP-5 cDNA
was cut out of the pGEM-T easy vector using BamHI and HindIII restriction enzymes and
ligated into the same sites of pREV-TRE vector.
Table 1. Conditions and sequences of primers used for quantitative PCR (Q-PCR) and RT-PCR








MKP-1 catcaaggatgctggaggga gaggtaagcaaggcagatggtg 64°C 64°C 4mM
MKP-2 ctgtacctcccagcaccaat actcgatggcttccatgaac 60°C
MKP-3 ccaacttggacgtgttggaa aatgcaccaggacaccacag 62°C 62°C 2mM
MKP-4 ggagcaaggcaggaacagagt ccaccagtaggcacgtgaaat 64°C 64°C 3mM
MKP-5 cttgcccttcctgttccttg agcaactgccccatgaagtt 62°C 64°C 3mM
MKP-6 gccttagcaggtgcagtagg tcccagggcacactaatttc 62°C 62°C 2mM
MKP-7 cagcgagatgtcctcaacaa taagcacacagccattggag 60°C 60°C 2mM
MKP-X ctgtccagatcctgccctac ccccatgaagttgaagttgg 62°C 64°C 3mM
DSP-2 attcatgagtgccgactcca cagcaccagcctgaactttg 60°C 60°C 2mM
VHR cgtctgtggctcaggacatc cattgagctggcagagttgg 60°C
36B4 aagcgcgtcctggcattgtct ccgcaggggcagcagtggt 64°C 3mM










The use of retroviruses is an efficient approach to deliver a mammalian expression vector
containing a gene of interest to a cell line (30). The viruses are modified so that they are no
longer able to replicate autonomously, but after packaging by the help of a packaging cell
line, the virus particles, containing recombinant DNA, can infect target cells. After
infection of the target cells the DNA is integrated into the genome, making it possible to
obtain cells that stably express the gene of interest. The expression vector contains a
selection marker that is used to select the cells that have been successfully infected.
The protocol from BD Biosciences was followed. Briefly, 2×105 BOSC cells were plated
out in 6cm2 dishes one day prior to transfection. Cells were transfected with 5µg pREV-
TRE/pREV-TRE-MKP-5 or pRevTet-Off by adding 75mM CaCl2, 100µM cloroquine and
Hepes buffer saline (to final concentrations of 16.8mM NaCl, 3mM Hepes and 90µM
Na2HPO4) to 4ml medium. 2×10
4 3T3-L1 cells were plated out in 6cm2 dishes one day
prior to infection with viral supernatant. Viral supernatant was collected from BOSC cells
48 hours post transfection and added to target cells in 4ml medium containing 1µg/ml
polybrene. Cells were grown to 70-80% confluence before selection with 200µg/ml
hygromycin for 6 days (pREV-TRE/pREV-TRE-MKP-5) or 400µg/ml neomycin
(pRevTet-Off) for 10 days. 3T3-L1 cells were sequentially infected and selected, first with
pREV-TRE/ pREV-TRE-MKP-5, then pRevTet-Off.
Western Blot analysis
Whole cell protein extracts from 3T3-L1 cells were prepared by resuspending cells in 80-
100µl of lysis buffer [0.1% Triton X-100, 20mM HePes (pH 7.7), 300mM NaCl, 0.2mM
EDTA, 1.5mM MgCl2, 0.5mM DTT, 20mM β -Glycerophosphate, 0.1mM
sodiumortovanadate, 0.5mM PMSF, and 2µg/ml leupeptin]. After two hours of rotation at
4°C, suspensions were centrifuged at 13000 rpm for 10 minutes. The post-nuclear
supernatant was collected and stored at -80°C. Protein concentrations were determined
using the Bio-Rad protein assay. 50-100µg of proteins were reduced by adding 100mM
DTT and heated to 100°C for 3 minutes prior to SDS-polyacrylamide gel electrophoresis
on 12-15% separating and 6% stacking gel. A Precision Plus Protein dual protein marker
was used as a molecular weight marker. The proteins were transferred to a PVDF
membrane activated in methanol. The blotted membrane was blocked in 5% milk in TBS-
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Tween for 1 hour prior to incubation with primary antibody overnight at 4°C. The
antibodies used were aP2 polyclonal antibody (1:2000), anti-phospho-ERK (phERK)
polyclonal antibody (1:1000), anti-total ERK polyclonal antibody (1:1000), anti-phospho-
JNK (phJNK) polyclonal antibody (1:500), anti-total JNK polyclonal antibody (1:1000),
and anti-α-Tubulin monoclonal antibody (1:4000). Two different anti-human MKP-5
antibodies were tested. The aP2 antiserum was IgG-purified before use, following the
protocol described in Molecular Cloning (3.rd edition, Sambrode and Russell). Secondary
antibodies used were horseradish peroxidase-conjugated anti-rabbit IgG antibody
(1:10000), horseradish peroxidase-conjugated anti-mouse IgG antibody (1:5000), and
horseradish peroxidase-conjugated anti-goat IgG antibody (1:8000). The enhanced
chemiluminescence kit was used for detection according to the manufacturer’s instructions.
Statistics
Statistical analysis was performed using the Student’s t-test. Values of p<0.05 were
considered significant.
Results
Regulation of MKP expression during adipogenesis and in mouse models of obesity
The mouse preadipocyte cell line 3T3-L1 was differentiated and used as a model system to
investigate expression and possible regulation of MKPs during adipogenesis.
Differentiation of 3T3-L1 adipocytes was confirmed by lipid staining and gene expression
analysis. Oil Red O staining of 3T3-L1 cells show a gradual accumulation of lipids during
adipogenesis by red staining of triglycerides and cholesteryl oleate (31). There was robust
Oil Red O staining after differentiation (Fig. 1A). Adipocyte-specific fatty acid binding
protein (aP2) is induced early in adipogenesis by the transcription factor C/EBPα (32). Up-
regulation of aP2 levels during adipogenesis was determined by quantitative PCR and
Western Blot analysis. As shown in Fig 1, levels of aP2 mRNA (Fig. 1B) and protein (Fig.




































Figure 1 – Differentiation of 3T3-L1 cells. Differentiation was induced in 100% confluent 3T3-L1 cells (day
0) using 0.5mM IBMX, 1µM dexamethasone and 5µg/ml insulin. After 48 hours in induction medium, the
cells were continuously stimulated with 5µg/ml insulin and harvested after 2, 4, 8, and 12 days.
Differentiation was verified by Oil Red O staining of lipids (panel A), and induced expression of aP2 mRNA
(normalized to 36B4 mRNA expression, relative to day –2 samples) (panel B) and aP2 protein (panel C)
analyzed by quantitative PCR and Western Blot analysis, respectively.
First, RT-PCR was performed on mRNA obtained from preadipocytes (50-60% confluent
3T3-L1 cells), fully differentiated 3T3-L1 cells (day 12), adipose tissue from mice, and cell
lines known to express MKPs (Hepa1c1c-7 and J55) to assess expression of different
MKPs and confirm that the primer sets were functional. MKP-1, MKP-2, MKP-3, MKP-4,
MKP-5, MKP-6, MKP-7, MKP-X, VHR, and DSP2 were all found to be expressed in
preadipocytes as well as in mature adipocytes and mouse adipose tissue (Supplementary
Fig. 1).
To analyze possible regulation of different MKPs during adipogenesis, quantitative PCR
was performed on mRNA isolated from 3T3-L1 cells harvested at different time-points
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during differentiation. Regulation of the different MKPs at the mRNA level is shown in
Fig. 2. MKP-1 and MKP-4 were down-regulated during adipogenesis starting after
induction of differentiation (at day 0). MKP-3, MKP-7, and MKP-X were down-regulated
at days 8 and 12 post induction. Most significant was the regulation of MKP-5 and MKP-6.
MKP-5 was significantly down-regulated at day 2 post induction and mRNA levels
increased slightly towards the end of adipogenesis. MKP-6 decreased at day 0, increased at
day 2 and finally decreased again. DSP2 was relatively stably expressed during
adipogenesis.
We then assessed the possible regulation of MKP expression in mouse models of obesity.
The ob/ob mouse is a frequently used model to study obesity. ob/ob mice display early-
onset obesity and insulin resistance, as well as hyperphagia, reduced energy expenditure
and infertility (7). Different tissues from ob/ob mice were tested for regulation of MKP
expression by quantitative PCR (Fig. 3A). MKP-1 was up-regulated in brown adipose
tissue (BAT) and subcutaneous adipose tissue. MKP-4 was highly up-regulated in
subcutaneous adipose tissue. MKP-5, MKP-6 and DSP2 were up-regulated in liver and
subcutaneous adipose tissue. MKP-7 was up-regulated in subcutaneous adipose tissue.
MKP-X was up-regulated in epididymal and subcutaneous adipose tissue. MKP-3 was not
significantly regulated. The same MKPs were also analyzed for regulation in Ay mice,
which is a different mouse model of obesity (33) (Fig. 3B). In general, the same pattern of
regulation is observed in Ay mice, although the MKPs seem to be less extensively
regulated. In contrast to what is observed in ob/ob mice, MKP-3 expression is reduced in





















































































































































































Figure 2- MKP mRNA levels during differentiation of 3T3-L1 cells. 3T3-L1 cells were induced to
differentiate and were then harvested at the indicated time points. Total RNA was isolated and converted to
cDNA and expression of MKP-1, MKP-3, MKP-4, MKP-5, MKP-6, MKP-7, MKP-X, and DSP2 was
measured by quantitative PCR (normalized to 36B4 mRNA expression, relative to day –2 samples). The
result presented is the average of three independent experiments +/-SE. * p <0.05 indicates significant
difference from –2 day samples.
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Figure 3- MKP mRNA levels in tissue samples from ob/ob, Ay, and wt mice. RNA was extracted from liver
tissue, muscle tissue, BAT, epididymal (epi) and subcutaneous (subc) white adipose tissues from ob/ob and
wt mice (panel A) and Ay and wt mice (panel B) and converted to cDNA. Expression of MKP-1, MKP-3,
MKP-4, MKP-5, MKP-6, MKP-7, MKP-X, and DSP2 was analyzed by quantitative PCR (normalized to 36B4
mRNA expression, relative to wt samples). Each sample was a pool from 2 mice.
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Ectopic expression of MKP-5 in 3T3-L1 cells enhances adipogenesis
MKP-5 expression was significantly regulated during adipogenesis (Fig. 2) as well as in
subcutaneous adipose tissue of ob/ob and Ay mice (Fig. 3A and 3B); it was therefore
chosen to study its possible effect on adipogenesis in 3T3-L1 cells by retroviral expression.
The full length MKP-5 cDNA (1500bp) was cloned from 3T3-L1 preadipocytes and
ligated into the expression vector pREV-TRE (Fig. 4A and 4B). Induced expression of
MKP-5 (8-12 fold) was verified on the mRNA level by quantitative PCR analysis (Fig.
4C). Western blot analysis was performed using two different antibodies, but an MKP-5
signal was not detected probably due to the fact that they were raised against the human








































Figure 4- Ectopic expression of MKP-5 in 3T3-L1 cells. The MKP-5 ORF was amplified from 3T3-L1
preadipocytes (panel B) and ligated into the pREV-TRE expression vector (panel A). 100% confluent cells
infected with pREV-TRE-MKP-5 or empty pREV-TRE retroviruses were induced to differentiate using 0.5mM
IBMX, 1µM dexamethasone and 5µg/ml insulin. After 48 hours in induction medium, the cells were
continuously stimulated with 5µg/ml insulin and harvested after 2, 4, and 8 days. Total RNA was converted
to cDNA and MKP-5 expression was analyzed by quantitative PCR (normalized to 36B4 mRNA expression,
relative to control samples) (panel C). The results shown are the average of three independent experiments
+/- SE. * p<0.05 indicates significant difference from control cells.
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3T3-L1 cells transfected with an empty vector (control) and cells ectopically expressing
MKP-5 were induced to differentiate in parallel. Lipid staining and gene expression
analysis was used to assess the extent of differentiation. Oil Red O staining indicated that
MKP-5 over-expressing cells had enhanced adipogenesis compared to control cells (Fig.
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Figure 5- Effect of MKP-5 expression on adipogenesis. 3T3-L1 cells ectopically expressing MKP-5 and
control cells were induced to differentiate using 0.5mM IBMX, 1µM dexamethasone and 5µg/ml insulin.
After 48 hours in induction medium, the cells were continuously stimulated with 5µg/ml insulin and
harvested after 2, 4, and 8 days. Differentiation was verified by Oil Red O staining of lipids (panel A), and
induced expression of aP2 mRNA (normalized to 36B4 mRNA expression, relative to day –2 sample) (panel
B) and aP2 protein (50µg) (panel C), analyzed by quantitative PCR and Western Blot analysis respectively.
Results shown here are representative of three individual experiments.
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ERK, but not JNK activity is regulated by MKP-5 in 3T3-L1 cells
MKP-5 has earlier been reported to dephosphorylate the MAPKs JNK, p38, and ERK (25).
To investigate whether MKP-5 regulates JNK and ERK activity in 3T3-L1 cells, levels of
phERK, total ERK, phJNK, and total JNK were examined by Western analysis of 3T3-L1
cells ectopically expressing MKP-5 compared with cells containing an empty expression
plasmid. In the absence of ectopic expression of MKP-5, phERK increased at day 0 and
then rapidly declined to low levels by day 2. This is consistent with previous work (18). At
day 4, phERK expression started to increase again. In the presence of MKP-5 expression,
the pattern of phERK expression during adipogenesis was the same, but there was
significantly more (60%) phERK at day -2 and less (30%) phERK at day 0 in cells
expressing MKP-5 (Fig. 6A). At day 4 post induction, phERK levels increased and at day 8
were back to levels observed at day -2.
In contrast, JNK activity was not regulated by MKP-5 expression (Fig. 6B). PhJNK levels
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Figure 6- ERK and JNK activity in differentiating 3T3-L1 cells over-expressing MKP-5 and control cells.
MKP-5 expressing cells and control cells were induced to differentiate, protein extracts (100µg) were
collected at indicated time-points and analyzed by Western blotting. Extracts were probed with phERK, total
ERK, and α-tubulin antibodies (panel A) and phJNK, total JNK, and α-tubulin antibodies (panel B). The
blots shown are representative of two individual experiments.
Discussion
The MKP family of dual specificity phosphatases has 14 identified members. Although
these proteins share common features, they are also known to differ in their function and
expression patterns. The expression and possible function of these proteins has mainly
been studied in specific human tissues, such as brain, heart, liver, and skeletal muscle,
where some show restricted expression (24, 34-39). MKP-4 has previously been shown to
be present in white adipose tissue and may contribute to its biology (28). In this study, we
found that all members of the MKP family tested were present in adipose tissue from
mouse, as well as in both preadipocytes and mature adipocytes of the 3T3-L1 cell line at
the mRNA level (Supplementary Fig. 1). In addition we showed that most of the MKPs are
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down-regulated during adipogenesis. We studied MKP-5 in more detail and found that
3T3-L1 cells differentiate more easily in response to ectopic expression of MKP-5.
Two MKPs have previously been investigated in relationship to adipogenesis, MKP-1 and
MKP-4. There are conflicting results regarding MKP-1. One group has shown an up-
regulation of MKP-1 during adipogenesis and that MKP-1 is the protein responsible for the
down-regulation of ERK activity that is known to occur after the initial stages of
differentiation (27). In contrast, another group has shown down-regulation of MKP-1
protein during differentiation of 3T3-L1 cells (18). In our work, we have shown that MKP-
1 is down-regulated at the mRNA level during adipogenesis, which is consistent with the
observations made in the latter report.
MKP-4 was previously reported to be up-regulated during adipogenesis in 3T3-F442A
cells, a cell line similar in properties to 3T3-L1 cells (40, 41). In contrast, we have found
that MKP-4 mRNA levels are down-regulated during differentiation of 3T3-L1 cells. Since
the cell lines used are different, this might indicate that the L1 and F442A cells may have
some different properties, which has also been previously reported (42, 43). Parallel
experiments in both cell lines are necessary in the future.
In this study we also investigate regulation of many of the other members of the MKP
family during differentiation of 3T3-L1 cells. In general they are all down-regulated to a
certain extent in terminally differentiated cells, except DSP2, which does not show
significant regulation during adipogenesis (Fig. 2). The time point at which the mRNA
levels of the different MKPs were down-regulated varied. Even though MKP-3 levels have
previously been reported to be unchanged during differentiation (up to day 8 post
induction) (27) we show a reduction of MKP-3 mRNA at day 12 post induction. The fact
that so many of the MKPs are regulated at the mRNA level during adipogenesis suggests
that they have a functional role in differentiation of 3T3-L1 cells.
MKP-4 was previously reported to be expressed and up-regulated in adipose tissue of
several rodent obesity models, including ob/ob mice (28). Consistent with these previously
published data, we found that MKP-4 was highly up-regulated in subcutaneous white
adipose tissue of ob/ob mice as well as in Ay mice (Fig. 3A and 3B). The same general
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picture also applied for MKP-1, MKP-5, MKP-6, MKP-7, and MKP-X (Fig. 3). The
previous study of MKP-4 established a link between this phosphatase and insulin signaling
(28). MKP-4 was up-regulated specifically in insulin-responsive tissues including liver,
muscle, white adipose tissue, and BAT. MKP-4 was also shown to reduce insulin-regulated
glucose uptake in 3T3-L1 cells.
MKP-4 was the first dual-specificity phosphatase to be implicated in insulin-resistance.
Before this the main focus was on protein-tyrosine phosphatases (PTPs). For instance, it is
well established that PTP-1b is a negative regulator of insulin action and a mediator of
insulin-resistance (44, 45). A study of PTP-1b deficient mice also showed that these
animals had low adiposity, linking this phosphatase directly to obesity (46). Given that
many of the MKPs are down-regulated in adipogenesis, yet show up-regulation in adipose
and other tissues of obese mice indicate that aspects of obesity other than increased fat
mass could influence the regulation of these proteins. Increased secretion of cytokines and
insulin-resistance, which is related to the obese state, might be factors that could effect the
expression and activity of MKPs.
Studies of MKP-1 and MKP-4 in adipocyte differentiation have established that members
of the MKP family are directly relevant to adipogenesis. MKP-1 expression has been
reported to be of physiological importance for adipocyte differentiation of 3T3-L1 cells,
while cells stably expressing MKP-4 were shown to differentiate poorly (27, 28). ERK and
p38 MAPK activity has been reported to be critical to initial phases of adipogenesis (15,
47-49). Previous studies have shown that MKP-5 can deactivate MAPKs (24, 25). Based
on this knowledge we hypothesized that since MKP-5 is significantly down-regulated early
in differentiation of 3T3-L1 cells (Fig. 2), ectopic expression of MKP-5 might have an
effect on differentiation, possibly through dephosphorylation of MAPKs. JNK activity was
not affected and the effect on p38 MAPK activity is unresolved, but an induction of ERK
activity was observed at day -2 and a reduction was observed at day 0 of treatment of 3T3-
L1 cells (Fig. 6). This indicates that in 3T3-L1 cells MKP-5 prefers ERK as a substrate to
JNK, in contrast to what is previously published in NIH-3T3 cells and COS-7 cells (24,
25). Anyhow, ERK activity was induced in day -2 cells. The results correlate with the
observation that a higher percentage of cells ectopically expressing MKP-5 differentiated
into mature adipocytes compared to the control cells, assessed by up-regulation of aP2 and
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increased lipid accumulation (Fig. 5). This might indicate a more complex role for MKP-5
than first assumed. Identification of other possible substrates and targets of MKP-5 in
adipocytes would be important in defining a potential function for MKP-5 in adipogenesis.
For instance a recent study reported that MKP-5 inhibits the TNF-α promoter in immune
cells (50); TNF-α is a known inhibitor of adipogenesis (51). Although the MAPKs are the
only identified substrates for the MKPs, other targets for dephosphorylation mediated by
the MKPs is of course possible. This has been an issue earlier, for instance c-Jun N-
terminal kinase, JNK, was first identified as a kinase that phosphorylates c-Jun, as the
name indicates (52). Later many other JNK substrates have been identified (53, 54). The
MKP family has mainly been studied regarding structure and ability to dephosphorylate
MAPKs, but much remains to be elucidated concerning biochemical and functional
aspects. Down-regulation of inhibitors of adipogenesis could give an explanation to the
observations made in this study.
Previous results state that ERK is active during initial stages of adipogenesis, and that
phosphorylated ERK is down-regulated around day 2-4 after induction of differentiation
(18, 27). Results presented here are consistent with this previously shown data in that ERK
is active in preadipocytes and confluent 3T3-L1 cells, but is down-regulated at day 2.
However, in our experiment, ERK activity reappears at day 4. The percentage of cells
differentiating into mature adipocytes in this study is somewhat lower than expected. It has
been shown that ERK acts negatively on adipogenesis by phosphorylation of PPARγ (14,
55). This could be the basis for the lesser degree of differentiation observed here.
Since results obtained in this study suggest a positive role for MKP-5 in adipogenesis, it
will be of interest to study this further. Establishing an inducible system where ectopic
expression of MKP-5 in 3T3-L1 cells can be controlled could verify if the results obtained
here are due to MKP-5 action as apposed to clonal differences between MKP-5 expressing
cells and control cells. Inhibitors of known signaling pathways could be used to assess
which factors that are involved in the down-regulation of MKP-5 during adipogenesis.
Experiments involving the ERK specific inhibitor, PD98059, could indicate if ERK
activity is required for the MKP-5 induced differentiation. Further studies of MKP-5 in
mouse models could give insight into the function of MKP-5 on adipose tissue formation
and adipogenesis in vivo. Knock-down studies of MKP-5 using RNA interference in 3T3-
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L1 cells and knockout of MKP-5 in mouse models of obesity could provide information on
the possible role of MKP-5 expression in adipogenesis, although it is known that many of
the members of the MKP family share the same substrate specificity and a certain degree
of redundancy seems likely (21). Studies in human mesenchymal stem cells and human
adipose tissue samples would also be important in investigating the role of MKP-5 in
human adipocyte differentiation and obesity. Studies in stem cells would give an indication
of a possible function for MKP-5 in lineage determination as well as in terminal
differentiation of adipocytes. Further work is necessary to assess these possibilities.
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Supplementary Figure 1 – Expression of MKPs in mouse adipose tissue and preadipocyte and fully
differentiated 3T3-L1 cells. Total RNA from Hepa1c1c-7 cells (H), J55 lymphocytes (J), mouse adipose
tissue (Ad), preadipocyte 3T3-L1 cells (-2d), and fully differentiated 3T3-L1 cells (+12d) was converted to
cDNA and expression of MKP-1, MKP-2, MKP-3, MKP-4, MKP-5, MKP-6, MKP-7, MKP-X, VHR, and
DSP2 was analyzed by RT-PCR. Hepa1c1c-7 cells and J55 cells were used as a positive control.  
